Bristol-Myers immunotherapy combo promising in melanoma: study

April 20, 2015 12:33 PM

2 0

(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.

The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.

Also read: Draghi Signals ECB Unlikely to Stop QE Plan Without Tapering

Read more

To category page